Hyaluronidase Via LADD Scleroderma-induced Microstomia
Microstomia, Scleroderma
About this trial
This is an interventional treatment trial for Microstomia
Eligibility Criteria
Inclusion Criteria: Patient being seen at the Lauritzen Outpatient Clinic or Westroads Clinic, Department of Dermatology Patient diagnosed with scleroderma-induced microstomia Capable and willing to participate No history of medical conditions that will interfere with successful completion of the study such as severe dementia or seizure disorder Patients aged 19 or older Exclusion Criteria: Pregnant and breastfeeding women Patients 18 years or younger In patients with bee stings or bites hyaluronidase is to be used cautiously Patients with infection or inflammation in or near the area of treatment Patients with prior treatment with hyaluronidase, LADD or ablative CO2 laser treatment, or have a history of adverse reactions to the treatments
Sites / Locations
- University of Nebraska Medical Center, Lauritzen Outpatient Center
- Nebraska Medicine, Dermatology Westroads
Arms of the Study
Arm 1
Experimental
Ablative CO2 laser, and intradermal hyaluronidase, via laser-assisted drug delivery
Uncover a safe, efficacious, and tolerable alternate treatment modality for patients with scleroderma-induced microstomia. Evaluate disease severity and patient quality of life before and after alternative treatment is administered